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Purpose of the study
In the Western world, approximately 30% of HIV-
infected individuals are still very late presenters. The aim
of this retrospective study is to describe epidemiological
and clinical characteristics, as well as long-term immuno-
logical outcome in virologically suppressed HIV+ very
late presenters.
Methods
We reviewed the medical records of all consecutive HIV+
patients with CD4 cell count < 200/ mmc3 at presenta-
tion, who had attended our clinic between 1996-2006,
and had achieved a persistent virological suppression for
at least 1 year. Demographic, clinical, virological and
immunological data at baseline and at follow up visits
were collected. The changes in CD4+ cell count during
follow up was also examined, stratifying the population
according to baseline age, HIV risk factors, CD4+ cell
counts, HIV viral load , HCV co-infection.
Summary of results
Overall 164 very late presenters with a persistent virolo-
gical response were examined. Caucasian and heterosex-
ual males represent the largest part of this cohort of
virological responder, very late presenter patients. IDUs
and HCV coinfected patients were under-represented as
compared to our HIV population, probably due to a
lower adherence. Epidemiological and clinical character-
istics of the study population: 61.2% had CD4+ cell count
<50/µl. 123 patients started a protease inhibitor-based
regimen (75%). Respectively 25% and 52% of initial
NNRTI and PI-based regimen were modified during
follow up (toxicity was the most common cause of
switch). After 5 years of therapy a good immunological
recovery (> 500 CD4 cell/µl) was observed in 30.7% and
46% of patients with baseline CD4+ cell count < 50/µl
and 51-200/µl respectively.
CD4+ cell count increased even after 5 years, reaching
a full immunological recovery (>700/µl) only in 17% of
patients. Patients aged ≥ 50 years, IDUs and HCV co-
infected had a slower and/or lower immune recovery;
no significant differences in immunological response
according to baseline viral load were observed.
Conclusions
A fair immune recovery over 5 years of HAART was
seen. The CD4+ cell count restoration was conditioned
by baseline values, age, HCV coinfection, and a com-
plete immunological recovery was achieved in a very
limited subset of patients.
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